Recent Advances in the
Treatment of Depression
June 1st, 2022
Registration is required
To all attendants via email
“Recent Advances in the Treatment of Depression”
June 1st, 2022 at 18:00 GMT
Depressive disorder is a mental disorder characterized by relapsing episodes which often develop eventually into chronic depression associated with high rates of disability and death by suicide. Because of its high prevalence, depression is the No1 cause of disability because of mental illness.
As most mental disorders, the onset of depression is during young adulthood, although it could manifest for the first time at any age. Psychotic symptoms, either congruent or non-congruent are not uncommon as well as cognitive impairment and significant disability. A significant proportion of patients will never recover completely and repeated hospitalizations or life-long protective living might be necessary for some. However the majority of patients will live a functional life, however with significant difficulty, distress and misery.
Social problems such as long-term unemployment, poverty, homelessness, exploitation, and victimization as well as problems with the law are commonly correlated with depression, and especially with its non-classic forms, which are complicated by the presence of personality disorders, substance and behavioral dependences, irritability and anger, as well as with hostility especially in psychotic cases. The treatment includes medication, along with psychotherapy, counseling and social rehabilitation.
The WPA webinar on Depression clinical management will be addressed mainly to the clinical doctors, who would like to enrich their practical experience in the treatment of Depressions in order to bring our patients back to their families and even to their job.
During the upcoming webinar you will have a unique opportunity not just to listen to the experts, but also to discuss your questions during Q&A sessions.
Prof. Siegfried Kasper
Dr. Siegfried Kasper is Professor Emeritus of Psychiatry and former Chairman of the Department of Psychiatry and Psychotherapy at the Medical University of Vienna, Austria. Born in Salzburg, Austria, he was educated at the medical schools of the University of Innsbruck, Austria and the Universities of Freiburg and Heidelberg, Germany. Dr. Kasper gained clinical and research experience in psychiatry at the Central Institute of Mental Health, Mannheim, Germany, the Psychiatric Department of the University of Heidelberg, Germany, the Clinical Psychobiology Branch of the National Institute of Mental Health, Bethesda, Maryland/USA, and the Psychiatric Department of the University of Bonn, Germany; in neurology at the Neurological Department of the University of Heidelberg in Mannheim; and psychotherapeutic and psychoanalytic training at the Ausbildungsinstitut für Psychotherapie und Psychoanalyse in Heidelberg/Mannheim, Germany.
Dr. Kasper published more than 600 in PubMed listed publications (Google: Citation Index: 51.746; Hirsch-Index: 112, i10-index: 719) and more than 250 books or book chapters, in various areas of psychiatry. He concentrates on the biological bases of mental disorders and their possible treatment approaches. Furthermore, he has conducted studies in psychopathological as well as clinical areas. Dr Kasper is a frequent national and international speaker and continues to be actively involved in research programmes studying depression, anxiety, psychosis, and dementia.
Dr. Kasper serves/served on the executive committees and advisory boards of several national and international societies, such as the Austrian Association of Psychiatry, Psychotherapy and Psychosomatic (ÖGPP), the European College of Neuropsychopharmacology (ECNP) and the European Psychiatric Association (EPA). From 2005 to 2009 Dr. Kasper was President of the World Federation of Societies of Biological Psychiatry (WFSBP) and has been appointed as Honorary President of the WFSBP in 2013. He has been elected to the Executive Committee of the International College of Neuropsychopharmacology (CINP) for the period of 2012 to 2018, served from 2018-2021 as President and is now immediate Past-President of this society. Moreover, Dr. Kasper was Chair of the World Psychiatric Association (WPA) Section of Pharmacopsychiatry from 2012-2019. He is Founding President of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry (ÖGPB) and of the Austrian Society of Drug Safety in Psychiatry (ÖAMSP). Furthermore, he is a Honorary Member of the Czech Society of Neuropsychopharmacology, the Romanian Society of Neuropsychopharmacology, the Hungarian Psychiatric Association and a Fellow of the Scandinavian College of Neuro-Psychopharmacology (SCNP) and of the Ukrainian Association of Psychiatry. He is a member of the Academia Europaea as well as the European Academy of Sciences and Arts (EASA). Dr. Kasper has been honored with the doctorate honoris causa of the Universities Craiova and Cluj-Napoca in Romania, as well as the Aristotle University in Thessaloniki in Greece.Furthermore, he has been appointed as Honorary/Visiting Professor at the following universities: University of Hong Kong, China, in 2004; Universidad Andrés Bello, Santiago de Chile, Chile, 2014; Aino University in Osaka, Japan, 2015; Kolkata Institute of Psychiatry, Department of Health & Family Welfare, India in 2016; University of Hiroshima, Japan, in 2017 and Belgrade University School of Medicine, Serbia, in 2017.
Prof. Michael Thase
Michael E. Thase is Professor of Psychiatry in the Department of Psychiatry of the Perelman School of Medicine of the University of Pennsylvania, and is also a member of the research faculty of the Corporal Michael J Crescenz Veterans Affairs Medical Center in Philadelphia.
A 1979 graduate of The Ohio State University College Medicine, Professor Thase completed internship, residency, chief residency, and post-doctoral training at the University of Pittsburgh Medical Center (UPMC), where he subsequently rose to the rank of Professor of Psychiatry and Chief of the Division of Academic Adult Psychiatry before moving to Philadelphia in 2007.
A Distinguished Life Fellow of the American Psychiatric Association, Professor Thase is renowned as a teacher, mentor, administrator, researcher and clinician. He has been elected to the membership of the American College of Psychiatrists, the American College of Neuropsychopharmacology and Penn Medicine’s Academy of Master Clinicians and is a Past President of the American Society of Clinical Psychopharmacology.
Professor Thase also is a Founding Fellow of the Academy of Cognitive Therapy, and a member of advisory boards for the Anxiety and Depressive Disorders Association, the National Network of Depression Centers, the Depression and Bipolar Support Alliance and the American Foundation for Suicide Prevention. One of the world’s most highly cited psychiatrists, Professor Thase’s 1000+ peer reviewed publications and book chapters, including a number of citation classics; the award-winning Learning Cognitive Therapy is among the 18 books that he has authored, co-authored or co-edited.
Professor Thase’s research has been continuously funded by federal agencies since the mid-1980s and currently focuses on novel pharmacotherapies for difficult to treat depressive disorders, as well as strategies to improve the dissemination and implementation of cost-effective forms of cognitive behavior therapy.